AstraZeneca COVID-19 Vaccine
- Generic Name
- AstraZeneca COVID-19 Vaccine
- Brand Names
- Vaxzevria
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2420395-83-9
- Unique Ingredient Identifier
- B5S3K2V0G8
- Background
The AstraZeneca COVID-19 Vaccine (previously known as ChAdOx1 nCoV-19 or AZD1222) is one of several vaccines developed in 2020 for the prevention of COVID-19 caused by SARS-CoV-2. The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for vaccines against another human coronavirus, Middle Eastern re...
- Indication
The AstraZeneca COVID-19 Vaccine is indicated for the active immunization of individuals 18 years of age and older for the prevention of COVID-19.
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19)
- Associated Therapies
- -
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Universiteit Antwerpen
- Target Recruit Count
- 580
- Registration Number
- NCT06189040
- Locations
- 🇧🇪
Centre for the Evaluation of Vaccination (CEV), Edegem, Antwerp, Belgium
🇧🇪Institute of Tropical Medicine (ITM), Antwerp, Belgium
🇧🇪Centre for Vaccinology (CEVAC), Ghent, East Flanders, Belgium
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Botswana Harvard AIDS Institute Partnership
- Target Recruit Count
- 10888
- Registration Number
- NCT05715944
- Locations
- 🇧🇼
Botswana Harvard Health Partnership, Gaborone, Botswana
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2848
- Registration Number
- NCT04973449
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Adaptive Immune Response to COVID-19 Vaccination
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 70
- Registration Number
- NCT04826770
- Locations
- 🇩🇪
University Medicine Greifswald, Greifswald, MV, Germany
Study of AZD1222 for the Prevention of COVID-19 in Japan
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT04568031
- Locations
- 🇯🇵
Research Site, Toshima-ku, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.